胸腺法新联合吉西他滨治疗晚期胰腺癌疗效观察

The Curative Effect Observation of Thymalfasin Combined with Gemcitabine in the Treatment of Advanced Pancreatic Cancer

目的:探讨胸腺法新联合吉西他滨治疗晚期胰腺癌疗效。方法:收集本院收治的胰腺癌患者50例,将患者按随机数字表法分为治疗组和对照组,每组25例。对照组患者采用吉西他滨单药化疗方案,治疗组在对照组基础上予以加用胸腺法新,比较两组的疗效差异。结果:治疗组体力状况改善有效率明显高于对照组,差异有统计学意义(P<0.05);对照组治疗前后T淋巴细胞群和NK细胞无明显变化(P>0.05);治疗后,治疗组的CD3+、CD4+升高,CD4+/CD8+比值下降,CD8+上升,差异均有统计学意义(P<0.05);治疗组的客观缓解率及稳定率均明显高于对照组,差异均有统计学意义(P<0.05);两组治疗后的不良反应例数与比较差异无统计学意义(P>0.05)。结论:胸腺法新联合吉西他滨治疗晚期胰腺癌疗效显著,具有明显改善免疫功能,且不增加不良反应发生风险。

Objective：To investigate the curative effect of Thymalfasin combined with gemcitabine in the treatment of advanced pancreatic cancer.Method：50 patients with pancreatic cancer were collected in our hospital, the patients were randomly divided into the treatment group and the control group, 25 cases in each group, the control group patients were treated by Gemcitabine chemotherapy, the treatment group combined with Thymalfasin in the based of control group, the difference of curative effect between groups were compared.Result：The physical condition effective improvement rate of the treatment group was higher than the control group, the difference was statistically significant（P〈0.05）. And T lymphocyte subsets and NK cells in the control group pre-therapy and post-therapy compared with no obvious change（P〉0.05）; after treatment, CD3^＋, CD4^＋ were increased,and CD4^＋/CD8^＋ of the treatment group ratio decreased, CD8^＋ was increased, the difference were statistically significant（P〈0.05）. The objective response rate and stable rate of the treatment group were significantly higher than the control group, the differences were statistically significant（〈P0.05）, the cases of adverse reactions in the two groups post-threapy had no significant difference（P〉0.05）. Conclusion：Thymalfasin combined with Gemcitabine have significant efficacy in the treatment of advanced pancreatic cancer, it can significantly improve immune function, and does not increase the risk of adverse reaction.